Therapeutic antisense oligonucleotides in oncology: from bench to bedside

Vista sencilla de ítem
dc.contributor.authorCakan, Elif
dc.contributor.authorLara, Olivia D.
dc.contributor.authorSzymanowska, Anna
dc.contributor.authorBayraktar, Emine
dc.contributor.authorChavez-Reyes, Arturo
dc.contributor.authorLopez-Berestein, Gabriel
dc.contributor.authorAmero, Paola
dc.contributor.authorRodriguez-Aguayo, Cristian
dc.date.accessioned2024-09-11T11:41:07Z
dc.date.available2024-09-11T11:41:07Z
dc.date.issued2024-08-23
dc.description.abstractAdvancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics have emerged as a promising frontier in this realm, offering novel avenues for intervention such as RNA interference and the utilization of antisense oligonucleotides (ASOs). ASOs represent a versatile class of therapeutics capable of selectively targeting messenger RNAs (mRNAs) and silencing disease-associated proteins, thereby disrupting pathogenic processes at the molecular level. Recent advancements in chemical modification and carrier molecule design have significantly enhanced the stability, biodistribution, and intracellular uptake of ASOs, thereby bolstering their therapeutic potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, and parasitic diseases, our review manuscript focuses specifically on the application of ASOs in targeted cancer therapies. Through a comprehensive examination of the latest research findings and clinical developments, we delve into the intricacies of ASO-based approaches to cancer treatment, shedding light on their mechanisms of action, therapeutic efficacy, and prospects.
dc.identifier.citationCancers, Vol. 16, N°17, 2940 (2024) p. 1-35.
dc.identifier.doihttps:// doi.org/10.3390/cancers16172940
dc.identifier.issne2072-6694
dc.identifier.orcidhttps://orcid.org/0000-0002-6655-815X
dc.identifier.urihttp://hdl.handle.net/20.500.12254/3845
dc.language.isoen
dc.publisherMDPI
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectAntisense oligonucleotides
dc.subjectNon-coding RNA
dc.subjectAntisense oligonucleotide delivery system
dc.subjectCancer therapy
dc.subjectGrb2.
dc.titleTherapeutic antisense oligonucleotides in oncology: from bench to bedside
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
cakan2024cancers herapeutic.pdf
Tamaño:
1.39 MB
Formato:
Adobe Portable Document Format
Descripción:
Texto completo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas